AstraZeneca

AstraZeneca Equity Ratio

Equity Ratio of AstraZeneca (AZN) as of Oct 19, 2026.

Equity Ratio

-

Last updated:

Equity Ratio of AstraZeneca is 2026 - . Equity Ratio of AstraZeneca was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AstraZeneca Stock analysis

What does AstraZeneca do? AstraZeneca PLC, listed on the stock market with ticker AZN, operates as a biopharmaceutical company focused on prescription medicines. Founded in the UK, it is headquartered in Cambridge, United Kingdom. The company develops, manufactures, and commercializes pharmaceutical products including Imjudo, Tagrisso, Imfinzi, Lynparza, Enhertu, and others. AstraZeneca's products target various therapeutic areas such as oncology, cardiovascular, respiratory, and immunology. The company went public on May 17, 1993. Its website is https://www.astrazeneca.com. AstraZeneca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AstraZeneca stock

On Eulerpool you can find the complete historical development of Equity Ratio AstraZeneca since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's AstraZeneca with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — AstraZeneca

All Key Metrics — AstraZeneca